As mentioned in the results section, TCGA data and our experimental studies, MSP, qPCR, western blot, and prostate cancer cells treated with 5-AZA-dC confirmed that NPTX2 expression in prostate cancer tissues was lower than that in control prostate tissues due to promoter methylation. The gene discussed is NPTX2; the disease is prostate carcinoma.